Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Symptomatic Hemoglobin New Mexico and a Case of Therapeutic Benefit with Acetazolamide

Ahmed Ayad, MD, Sara Nofal, MD, Crystal Jobson, MD, Yuval Raizen, MD, Mona Lisa Alattar, MD

Blood (2018) 132 (Supplement 1): 4918.

https://doi.org/10.1182/blood-2018-99-119250

Published: 2018

Journal Articles

Analysis Of Responses (complete cytogenetic response and major molecular response) Achieved With Different Tyrosine Kinase Inhibitor (TKI) Modalities and Their Impact On Long Term Outcomes In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) – Analysis From a Single Institution

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Mona Lisa Alattar, MD, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Marylou Cardenas-Turanzas, MD, Dr PH, Carlos Guillermo Romo, MD, Sara E Dellasala, RN, Sherry Pierce, Srdan Verstovsek, MD, PhD, Farhad Ravandi, MD, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2728.

https://doi.org/10.1182/blood.V122.21.2728.2728

Published: 2013

Journal Articles

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT -3 internal tandem duplication mutation

Blood (2013) 121 (23): 4655–4662.

https://doi.org/10.1182/blood-2013-01-480228

Published: 2013

Includes: Supplemental data

Journal Articles

Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3 -ITD mutation

Farhad Ravandi, MD, Mona Lisa Alattar, MD, Mark J. Levis, MD, PhD, Guillermo Garcia-Manero, MD, Mary A Richie, RN, Naval G. Daver, MD, Stefan Faderl, MD, Michael Andreeff, MD, PhD, Gautam Borthakur, M.D., Jan A. Burger, MD, PhD, Tapan M. Kadia, M.D., Michael R. Grunwald, MD, Sara E Dellasala, RN, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 1519.

https://doi.org/10.1182/blood.V120.21.1519.1519

Published: 2012

Journal Articles

Incidence and Outcomes of a Rare Translocation t(3,5) in Patients (pts) with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Mona Lisa Alattar, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., Maro Ohanian, DO, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Alfonso Quintas-Cardamas, MD, Elias Jabbour, Naval Daver, MD, Sherry A. Pierce, RN, BS, Mark Brandt, BS, Stefan Faderl, MD, Naveen Pemmaraju, M.D.

Blood (2012) 120 (21): 1456.

https://doi.org/10.1182/blood.V120.21.1456.1456

Published: 2012

Journal Articles

Myeloid Sarcoma of the Orbit and Ocular Adnexae

Maro Ohanian, DO, Mona Lisa Alattar, MD, Zeev Estrov, MD, PhD, Alfonso Quintas-Cardama, MD, John T Manning, MD, Farhad Ravandi, MD, Lynne V. Abruzzo, MD, PhD, Jorge E. Cortes, MD, Naveen Pemmaraju, M.D.

Blood (2012) 120 (21): 1463.

https://doi.org/10.1182/blood.V120.21.1463.1463

Published: 2012

Journal Articles

Very Long-Term Follow-up Results of Imatinib Mesylate Therapy in Chronic Phase Chronic Myeloid Leukemia After Failure of Interferon Alpha Therapy

Mona Lisa Alattar, MD, Jorge E. Cortes, Susan O'Brien, MD, Guillermo Garcia-Manero, Stefan Faderl, MD, Farhad Ravandi, MD, Elias Jabbour, Jianqin Shan, PhD, Hagop M. Kantarjian

Blood (2011) 118 (21): 2749.

https://doi.org/10.1182/blood.V118.21.2749.2749

Published: 2011

Journal Articles

Clinical Significance of Complete Cytogenetic Response (CCyR) and Major Molecular Response (MMR) Achieved with Different Treatment Modalities Used As Frontline Therapy In Chronic Myeloid Leukemia (CML) Chronic Phase (CP)

Mona Lisa Alattar, MD, Hagop M. Kantarjian, Elias Jabbour, Alfonso Quintas-Cardama, MD, Elizabeth M Burton, Gautam Borthakur, Srdan Verstovsek, MD, PhD, William G. Wierda, MD, PhD, Marina Konopleva, M.D., Ph.D., Jan A. Burger, MD, PhD, Susan O'Brien, MD, Jorge E. Cortes

Blood (2011) 118 (21): 745.

https://doi.org/10.1182/blood.V118.21.745.745

Published: 2011

NARROW

Symptomatic Hemoglobin New Mexico and a Case of Therapeutic Benefit with Acetazolamide

Analysis Of Responses (complete cytogenetic response and major molecular response) Achieved With Different Tyrosine Kinase Inhibitor (TKI) Modalities and Their Impact On Long Term Outcomes In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) – Analysis From a Single Institution

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT -3 internal tandem duplication mutation

Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3 -ITD mutation

Incidence and Outcomes of a Rare Translocation t(3,5) in Patients (pts) with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Myeloid Sarcoma of the Orbit and Ocular Adnexae

Very Long-Term Follow-up Results of Imatinib Mesylate Therapy in Chronic Phase Chronic Myeloid Leukemia After Failure of Interferon Alpha Therapy

Clinical Significance of Complete Cytogenetic Response (CCyR) and Major Molecular Response (MMR) Achieved with Different Treatment Modalities Used As Frontline Therapy In Chronic Myeloid Leukemia (CML) Chronic Phase (CP)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only